• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FLGC alert in real time by email
    SC 13D/A 1 ef20040315_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    AMENDMENT NO. 5 TO
    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
     
    Flora Growth Corp.
    (Name of Issuer)
     
    Common Shares, no par value
    (Title of Class of Securities)

    339764102
    (CUSIP Number)
     
    Clifford Starke
    Pia Porras 75 San Francisco
    Panama City, Panama
     
    With a copy to:
     
    Richard Raymer
    Dorsey & Whitney LLP
    66 Wellington Street W., Suite 3400
    Toronto, Ontario M5K 1E6 Canada
    (416) 367-7370
     
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 15, 2024
    (Date of Event which Requires Filing of this Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    CUSIP No. 339764102
     
    1
    NAMES OF REPORTING PERSONS
     
     
    Clifford Starke (the “Reporting Person”)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF and OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
    Not Applicable
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    3,850,886
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    3,850,886
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,850,886
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    NOT APPLICABLE
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.1%(1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    (1)
    The percentages used herein are calculated based upon 18,511,898 outstanding shares of the Issuer as of December 15, 2024, plus 1,603,984 shares underlying unvested stock appreciation rights owned by the Reporting Person.


    CUSIP No. 339764102
     
    Reference is hereby made to the statement on Schedule 13D filed with the Securities and Exchange Commission on January 6, 2023 (the “Schedule 13D”), with respect to the Common Stock, no par value (the “Common Stock”), of Flora Growth Corp., an Ontario Corporation (the “Issuer”), as amended on April 21, 2023, November 15, 2023, and April 15, 2024, and September 11, 2024. Capitalized terms not otherwise defined herein are used as defined in the Schedule 13D, as amended. The Reporting Person hereby amends and supplements the Schedule 13D as follows.

    Item 1.
    Security and Issuer
     
    (a)
    Title of Class of Securities:
     
    Common Shares, no par value
     
    (b)
    Name of Issuer:
     
    Flora Growth Corp., an Ontario corporation
     
    (c)
    Address of Issuer’s Principal Executive Offices:
     
    3230 W. Commercial Blvd., Suite 180
    Fort Lauderdale, FL 33309
     
    Item 2.
    Identity and Background
     
    (a)
    Name of Reporting Person:
     
    Clifford Starke
     
    (b)
    Principal Business Address:
     
    The principal business address of the Reporting Persons is: 3230 W. Commercial Blvd., Suite 180, Fort Lauderdale, FL 33309
     
    (c)
    Occupation, Employment and Other Information:
     
    The Reporting Person is a director and the Chief Executive Officer of the Issuer.
     
    (d)
    Criminal convictions:
     
    The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
     
    (e)
    Civil proceedings:
     
    The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which the Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
     
    (f)
    Citizenship:
     
    Canada
     
    Item 3.
    Source and Amount of Funds or Other Consideration

    PF and OO


    Item 4.
    Purpose of Transaction
     
    The transactions described in Item 5(c) below were made in the ordinary course of business and the Reporting Person has no plans or proposals regarding the acquisition or disposition of securities of the Issuer outside of the ordinary course of business that would result in an extraordinary corporate transaction, a sale or transfer of material assets of the Issuer or its subsidiaries, a change in the current board of directors or management of the Issuer, including the number or term of existing directors or to fill any vacancies on the board of directors of the Issuer, any material change in the present capitalization or dividend policy of the Issuer, any other material change in the Issuer’s business or corporate structure, any changes to the Issuer’s charter, bylaws or instruments corresponding thereto or any other actions which may impede the acquisition of control of the Issuer by any person, any action to cause a class of the Issuer to be delisted from a national securities exchange or cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, any action resulting in eligibility for termination of registration of the Issuer’s securities pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended, or any other similar action.
     
    Item 5.
    Interests in Securities of the Issuer:
     

    (a)
    and (b).  As of December 15, 2024, the Reporting Person holds the following shares of Common Stock:
     
    Number of shares as to which the Reporting Person has:
     

    (i)
    Sole power to vote or to direct the vote:  3,850,886
     

    (ii)
    Shared power to vote or to direct the vote: 0
     

    (iii)
    Sole power to dispose or direct the disposition:  3,850,886
     

    (iv)
    Shared power to dispose or direct the disposition: 0
     

    (v)
    Aggregate amount of shares beneficially owned:  3,850,886
     

    (vi)
    Percent of class represented in Item (v) above:  19.1%
     
    (c)  On September 13, 2024, the Reporting Person purchased 6,795 shares of the Issuer’s common stock, at $0.95 per share for a total purchase price of $611.55.
     
    On December 15, 2024, the Issuer granted 900,000 restricted stock awards, with immediate vesting, to the Reporting Person.
     
    (d) None
     
    (e) Not applicable
     
    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
     
    Other than described in this Amended Schedule 13D, to the knowledge of the Reporting Person there are no other contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to the securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option agreements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
     
    Item 7.
    Materials to be Filed as Exhibits
     
    Not applicable


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date: December 17, 2024
     
       
     
    /s/ Clifford Starke
     
     
    Clifford Starke

     

    Get the next $FLGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLGC

    DatePrice TargetRatingAnalyst
    11/25/2024$4.00Buy
    Aegis Capital
    10/13/2021$10.00Buy
    Roth Capital
    6/23/2021$6.00Buy
    MKM Partners
    More analyst ratings

    $FLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital initiated coverage on Flora Growth with a new price target

      Aegis Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $4.00

      11/25/24 8:07:10 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Flora Growth with a new price target

      Roth Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $10.00

      10/13/21 9:00:51 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MKM Partners initiated coverage on Flora Growth with a new price target

      MKM Partners initiated coverage of Flora Growth with a rating of Buy and set a new price target of $6.00

      6/23/21 5:36:01 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    SEC Filings

    See more
    • SEC Form EFFECT filed by Flora Growth Corp.

      EFFECT - Flora Growth Corp. (0001790169) (Filer)

      5/23/25 12:15:17 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Flora Growth Corp.

      S-3 - Flora Growth Corp. (0001790169) (Filer)

      5/14/25 4:02:08 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Flora Growth Corp.

      10-Q - Flora Growth Corp. (0001790169) (Filer)

      5/13/25 4:56:00 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woo Edward was granted 50,000 shares, increasing direct ownership by 59% to 134,698 units (SEC Form 4)

      4 - Flora Growth Corp. (0001790169) (Issuer)

      12/17/24 10:22:07 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wolkin Harold

      4 - Flora Growth Corp. (0001790169) (Issuer)

      12/17/24 10:19:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO Vaiman Dany

      4 - Flora Growth Corp. (0001790169) (Issuer)

      12/17/24 10:01:07 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care